Phosphatidylinositol 3-Kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-Apoptotic activity in ovarian cancer cells

Pharmaceutical Research

Volumn 29, Issue 10, 2012, Pages 2874-2886

  Talekar, Meghna ^a   Ganta, Srinivas ^b   Singh, Amit ^c   Amiji, Mansoor ^c   Kendall, Jackie ^d   Denny, William A ^d   Garg, Sanjay ^a,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Nemucore Medical Innovations   (United States)

^c NORTHEASTERN UNIVERSITY   (United States)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

C6 Ceramide; EGFR; Folate; Nanoemulsion; Ovarian cancer.; Phosphatidylinositol 3 Kinase inhibitor

Indexed keywords

CERAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IC 50; NANOEMULSION; OVARY CANCER; PRIORITY JOURNAL; SURFACE PROPERTY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CELL SURVIVAL; CERAMIDES; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; EMULSIONS; FEMALE; HUMANS; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84866729798     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0793-6     Document Type: Article

References (41)

1. Society AC. Ovarian Cancer. 2012; Available from: http://www.cancer.org/ Cancer/OvarianCancer/DetailedGuide/ovariancancer-key-statistics.
2. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci U S A. 2007;104(13):5569-74.
3. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A. 2006;103(5):1475-9.
4. Frédérick R, Mawson C, Kendall JD, Chaussade C, Rewcastle GW, Shepherd PR, Denny WA. Phosphoinositide-3-kinase (PI3K) inhibitors: Identification of new scaffolds using virtual screening. Bioorg Med Chem Lett. 2009;19(20):5842-7.
5. Hu L, Hofmann J, Lu Y,Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 2002;62(4):1087-92.
6. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer. 2006;94(4):455-9.
7. Marone R, Cmiljanovic V, Giese B, Wymann M. Targeting phosphoinositide 3-kinase-Moving towards therapy. Biochim Biophys Acta Protein Proteonomics. 2008;1784(1):159-85.
8. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther. 2008;118 (2):192-205.
9. Maira SM, Voliva C, Garcia-Echeverria C. Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets. 2008;12 (2):223-38.
10. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, Loewith R, Stokoe D, Balla A, Toth B, Balla T, Weiss WA, Williams RL, Shokat KM. A Pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell. 2006;125(4):733-47.
11. Chaussade C, Rewcastle GW, Kendall JD, Denny WA, Cho K, Grønning LM, Chong ML, Anagnostou SH, Jackson SP, Daniele N, Shepherd PR. Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem J. 2007;404(3):449-58.
12. Kendall JD, Rewcastle GW, Frederick R, Mawson C, Denny WA, Marshall ES, Baguley BC, Chaussade C, Jackson SP, Shepherd PR. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110[alpha] inhibitors. Bioorg Med Chem. 2007;15(24):7677-87.
13. Hayakawa M, Kawaguchi KI, Kaizawa H, Koizumi T, Ohishi T, Yamano M, Okada M, Ohta M, Tsukamoto SI, Raynaud FI, Parker P, Workman P, Waterfield MD. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110a inhibitors. Bioorg Med Chem. 2007;15(17):5837-44.
14. Dagia NM, Agarwal G, Kamath DV, Chetrapal-Kunwar A, Gupte RD, Jadhav MG, Dadarkar SS, Trivedi J, Kulkarni-Almeida AA, Kharas F, Fonseca LC, Kumar S, Bhonde MR. A preferential p110a/? PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-?B-dependent manner. Am J Physiol Cell Physiol. 2010;298(4):C929-41.
15. Tiwari SB, Amiji MM. Improved oral delivery of paclitaxel following administration in nanoemulsion formulations. J Nanosci Nanotechnol. 2006;6(9-10):3215-21.
16. Lo Prete AC, Maria DA, Rodrigues DG, Valduga CJ, Ibañez OCM, Maranhão RC. Evaluation in melanoma-bearing mice of an etoposide derivative associated to a cholesterol-rich nanoemulsion. J Pharm Pharmacol. 2006;58(6):801-8.
17. Ohguchi Y, Kawano K, Hattori Y, Maitani Y. Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: Effect of chain length and amount of folate-PEG linker. J Drug Target. 2008;16(9):660-7.
18. Tagne JB, Kakumanu S, Nicolosi RJ. Nanoemulsion preparations of the anticancer drug dacarbazine significantly increase its efficacy in a xenograft mouse melanoma model. Mol Pharm. 2008;5 (6):1055-63.
19. Tagne JB, Kakumanu S, Ortiz D, Shea T, Nicolosi RJ. A nanoemulsion formulation of tamoxifen increases its efficacy in a breast cancer cell line. Mol Pharm. 2008;5(2):280-6.
20. Kawakami S, Yamashita F,Hashida M.Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Adv Drug Deliv Rev. 2000;45(1):77-88.
21. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm. 2011;8(1):185-203.
22. Magadala P, Amiji M. Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J. 2008;10(4):565-76.
23. Liu Y, Sun J, Cao W, Yang J, Lian H, Li X, Sun Y, Wang Y, Wang S, He Z. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm. 2011;421 (1):160-9.
24. Kang C, Yuan X, Zhong Y, Pu P, Guo Y, Albadany A, Yu S, Zhang Z, Li Y, Chang J, Sheng J. Evaluation of folate-PAMAM for the delivery of antisense oligonucleotides to rat C6 glioma cells in vitro and in vivo. J Biomed Mater Re. 2010;93(2):585-94.
25. Leamon CP, Low PS. Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target. 1994;2(2):101-12.
26. Asadishad B, Vossoughi M, Alemzadeh I. Folate-receptor-targeted delivery of doxorubicin using polyethylene glycol-functionalized gold nanoparticles. Ind Eng Chem Res. 2010;49(4):1958-63.
27. Huang W, Chen, C., Lin, Y, Lin, C. Apoptotic sphingolipid ceramide in cancer therapy. Journal of Lipids. 2011;2011.
28. Van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer. Cancer Res. 2007;67(10):4843-50.
29. Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer. 2007;121(8):1830-8.
30. Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, Xu Y, Gu J. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J. 2005;19(14):1978-85.
31. Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, Xu Y. Peptide ligandmediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(1-2):155-61.
32. van Vlerken LE, Duan Z, Little SR, Seiden MV, Amiji MM. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm. 2008;5 (4):516-26.
33. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928-39.
34. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 2010;99 (11):4630-41.
35. Ganta S, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm. 2008;360(1-2):115-21.
36. Talekar M, Kendall J, Denny W, Garg S. Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anti Canc Drugs. 2011;22(10):949-62.
37. Werner ME, Karve S, Sukumar R, Cummings ND, Copp JA, Chen RC, Zhang T, Wang AZ. Folate-targeted nanoparticle delivery of chemo-and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis. Biomaterials. 2011;32(33):8548-54.
38. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PlK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999;21(1):99-102.
39. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R. Folate-receptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 2008;16(5):415-23.
40. Orth JD, Krueger EW, Weller SG, McNiven MA. A novel endocytic mechanism of epidermal growth factor receptor sequestration and internalization. Cancer Res. 2006;66(7):3603-10.
41. ThevissenK, François IEJA, Winderickx J, Pannecouque C, Cammue BPA. Ceramide involvement in apoptosis and apoptotic diseases. Mini-Reviews in Medicinal Chem. 2006;6(6):699-709.